Loading...
•
Dec 31, 2020
Bioventus Q4 2020 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2020.
Key Takeaways
Bioventus Inc. reported Q4 2020 net sales of $98.6 million, a 1% increase year-over-year. The company's net income from continuing operations was $2.3 million. Adjusted EBITDA was $28.2 million, down 8% year-over-year.
Net sales increased by 1% year-over-year, reaching $98.6 million.
U.S. net sales increased by 3% year-over-year to $89.7 million, while international net sales decreased by 17% year-over-year to $8.9 million.
Net income from continuing operations decreased by 58% year-over-year to $2.3 million.
Adjusted EBITDA decreased by 8% year-over-year to $28.2 million.
Revenue by Geographic Location
Forward Guidance
For the twelve months ending December 31, 2021, the Company expects net sales of $360 million to $372 million, net income attributable to common shareholders of $15 million to $19 million, Non-GAAP net income attributable to common shareholders of $43 million to $46 million, and Adjusted EBITDA of $79 million to $83 million.
Positive Outlook
- Net sales are expected to be between $360 million and $372 million.
- Net income attributable to common shareholders is projected to be $15 million to $19 million.
- Non-GAAP net income attributable to common shareholders is expected to be $43 million to $46 million.
- Adjusted EBITDA is anticipated to be $79 million to $83 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...